Latest News and Press Releases

Celex Oncology, a UK biotechnology on the brink of launching the fourth revolution in cancer care, today announced their investigative model and treatment.

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The award aims to recognise the most creative and impactful sponsorship activations in the international sports landscape Capgemini’s sponsorship...

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...

New York, Dec. 12, 2023 (GLOBE NEWSWIRE) -- According to the market.us, the global nanomedicine market reached a value of USD 153 billion in 2023 and is projected to witness substantial growth,...

Austin, TX, USA, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “6G Market Size, Trends and Insights By Technology (Terahertz Communication,...

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...

New York, New York, April 11, 2022 (GLOBE NEWSWIRE) -- International real estate developer Robbie Antonio has announced his upcoming plans to begin a series of spec home development projects...

NANOBIOTIX ANNONCE LA TOUTE PREMIERE AUTORISATION DE MISE SUR LE MARCHÉ EUROPEEN D’UN RADIOENHANCER Hensify®(NBTXR3) a reçu une autorisation de mise sur le marché (Marquage CE) en Europe...

NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union...

Atlanta, GA, Sept. 2, 2011 (GLOBE NEWSWIRE) -- Inc. magazine ranked The Rainmaker Group No. 2907 on its annual Inc. 500|5000 list, an exclusive ranking of the nation's fastest-growing private...